Edgewise Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 133

Employees

  • Stock Symbol
  • EWTX

Stock Symbol

  • Share Price
  • $41.17
  • (As of Thursday Closing)

Edgewise Therapeutics General Information

Description

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1715 38th Street
  • Boulder, CO 80301
  • United States
+1 (720)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1715 38th Street
  • Boulder, CO 80301
  • United States
+1 (720)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Edgewise Therapeutics Stock Performance

As of 19-Nov-2026, Edgewise Therapeutics’s stock price is $41.17. Its current market cap is $4.51B with 109M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$41.17 $41.37 $19.76 - $48.78 $4.51B 109M 1.53M $9.35

Edgewise Therapeutics Financials Summary

As of 30-Sep-2026, Edgewise Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,952,209 2,067,966 2,040,087 410,103
Revenue 0 0 0 0
EBITDA 1,135,303 (189,140) (156,542) (112,625)
Net Income 1,009,595 (167,795) (133,813) (100,163)
Total Assets 1,780,020 552,603 486,817 340,035
Total Debt 3,383 3,990 4,737 5,414
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Edgewise Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Edgewise Therapeutics‘s full profile, request access.

Request a free trial

Edgewise Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Edgewise Therapeutics‘s full profile, request access.

Request a free trial

Edgewise Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscula
Drug Discovery
Boulder, CO
133 As of 2026

Waltham, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Edgewise Therapeutics Competitors (8)

One of Edgewise Therapeutics’s 8 competitors is Dyne Therapeutics, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dyne Therapeutics Formerly VC-backed Waltham, MA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Solid Biosciences Formerly VC-backed Charlestown, MA
Cytokinetics Formerly VC-backed South San Francisco, CA
Epirium Bio Venture Capital-Backed San Diego, CA
You’re viewing 5 of 8 competitors. Get the full list »

Edgewise Therapeutics Patents

Edgewise Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026102326-A1 Pyridazinone compositions and methods for the treatment of muscular conditions Pending 08-Nov-2024
WO-2026076029-A1 Thiadiazine compounds and uses thereof Pending 02-Oct-2024
WO-2025217000-A1 1,4-dihydroquinazolinone compositions for the treatment of cardiac conditions Pending 12-Apr-2024
WO-2025207679-A1 Quinazoline dione compounds and uses thereof Pending 26-Mar-2024
WO-2025207677-A1 Quinazolinone compounds and uses thereof Pending 26-Mar-2024 C07D471/04
To view Edgewise Therapeutics’s complete patent history, request access »

Edgewise Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Edgewise Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Edgewise Therapeutics‘s full profile, request access.

Request a free trial

Edgewise Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.63 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Edgewise Therapeutics’s complete esg history, request access »

Edgewise Therapeutics FAQs

  • When was Edgewise Therapeutics founded?

    Edgewise Therapeutics was founded in 2017.

  • Where is Edgewise Therapeutics headquartered?

    Edgewise Therapeutics is headquartered in Boulder, CO.

  • What is the size of Edgewise Therapeutics?

    Edgewise Therapeutics has 133 total employees.

  • What industry is Edgewise Therapeutics in?

    Edgewise Therapeutics’s primary industry is Drug Discovery.

  • Is Edgewise Therapeutics a private or public company?

    Edgewise Therapeutics is a Public company.

  • What is Edgewise Therapeutics’s stock symbol?

    The ticker symbol for Edgewise Therapeutics is EWTX.

  • What is the current stock price of Edgewise Therapeutics?

    As of 19-Nov-2026 the stock price of Edgewise Therapeutics is $41.17.

  • What is the current market cap of Edgewise Therapeutics?

    The current market capitalization of Edgewise Therapeutics is $4.51B.

  • Who are Edgewise Therapeutics’s competitors?

    Dyne Therapeutics, Sarepta Therapeutics, Solid Biosciences, Cytokinetics, and Epirium Bio are some of the 8 competitors of Edgewise Therapeutics.

  • What is Edgewise Therapeutics’s annual earnings per share (EPS)?

    Edgewise Therapeutics’s EPS for 12 months was $9.35.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process